DETAILS, FICTION AND CLINICAL TRIAL RECRUITMENT FOR ABBV-744 STUDY

In Section A, participants will acquire distinctive doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. Added participants will be enrolled within the determined monotherapy dosign regimen. In Section B, participants will acquire oral ruxolitinib and ABBV-744 is going to be provided as "increase-on" therapy. In Section C